Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
aliskiren · 1 trial · 1 indication
as measured by PAH clearance
| Arm | Type | Description |
|---|---|---|
| VTP-27999 | EXPERIMENTAL | - |
| aliskiren | ACTIVE_COMPARATOR | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| aliskiren | DRUG | single dose, tablet |
| placebo | DRUG | single dose, tablet |
| VTP-27999 | DRUG | single dose, tablet |
Inclusion Criteria: * Healthy adult male or female, 18-75 years of age * Female subjects must be postmenopausal or surgically sterilized. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by plasma serum...
Aliskiren is a small molecule being studied for its effects on renal function. It is currently in Phase 1 clinical development as an investigational therapy. The drug has been evaluated in a completed clinical trial involving healthy volunteers to assess its impact on the kidney.
Aliskiren is being developed by Syndax Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SNDX. The company is conducting clinical research on this small molecule for renal function applications.
Aliskiren is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical testing. The Phase 1 trial for aliskiren has been completed.
Aliskiren has been studied in a completed Phase 1 clinical trial with the identifier NCT01217736, titled "Direct Renin Inhibition and the Kidney." This trial enrolled 22 participants in the United States, including healthy volunteers, and was placebo-controlled.
Aliskiren is a distinct investigational small molecule developed by Syndax Pharmaceuticals. It is being studied for its effects on renal function. No alternative names for aliskiren have been established in the available clinical trial information.